The Paust Lab
Members of the Paust laboratory are interested in the development and testing of novel immunotherapies that elicit clinically relevant Natural Killer cell-mediated anti-pathogen or anti-tumor immunity.
Principal Investigator
Location
Connect
Topics
Members of the Paust laboratory are interested in the development and testing of novel immunotherapies that elicit clinically relevant Natural Killer cell-mediated anti-pathogen or anti-tumor immunity. Our research program is centered on the discovery that subsets of NK cells are long-lived and capable of antigen-specific immunological memory to viruses and altered self, giving precedence to investigations that seek to exploit NK cell activity to prevent or cure disease. Currently, we are pursuing three specific scientific goals: 1) Identification of the mechanisms by which subsets of murine and human NK cells mediate antigen-specific immunological memory responses; 2) Identification of NK cell-specific immune correlates of protection from infection or malignancy; 3) Development of effective, host-protective vaccine or therapeutic approaches that elicit potent NK cell-mediated recall responses in vivo. To enable our studies, we routinely utilize mouse models, xenograft models, and clinical samples for the immunological analyses of innate and adaptive NK cell-mediated immune responses.
-
Media ReleaseOctober 29, 2024JAX researchers unveil method to map immune cell connections, predicting patient survival in cancer
Researchers at The Jackson Laboratory have developed a new combination of imaging and computational methods to study connections between immune cells in breast cancer and melanoma -
Research HighlightJune 05, 2024Revealing potential therapy targets for cancer
Reenergizing exhausted T cells, with help from a rare immune cell known as a basophil, can kickstart the immune system into fighting cancer. -
Featured ArticleMay 08, 2024Paige Ramkissoon reflects on postbac at JAX
Paige Ramkissoon reflects on how her time in the JAX Postbac program has prepared her for the next step in her academic training. -
Research HighlightApril 23, 2024Investigating age-related immune dysfunction in lung epithelial cells
With $13 million in renewed support, Karolina Palucka will further study how aging affects airway epithelial cells’ efficiency in combating viral infections.
-
ArticleOctober 08, 2024Cancer research trainees advance their skills at JAX with support from the American Cancer Society
Earlier this year, The Jackson Laboratory’s NCI-designated Basic Research Cancer Center and the American Cancer Society (ACS) teamed up to have ACS-funded trainees attend advanced cancer courses at JAX, aiming to deepen their understanding of cutting-edge cancer research techniques through experiential learning. -
Blog PostJune 04, 2024The inner space of cancer
New methods allow researchers to figure out what happens where in tumors, with important implications for improving cancer therapies. -
ArticleMay 01, 2024Cancer patients gain important benefits from genome-matched treatments
A study from MCGI indicates that Maine cancer patients experienced better outcomes following genomic tumor testing to guide targeted therapy strategies; but a gap between testing and clinical delivery still exists. -
Press ReleaseMarch 11, 2024JAX and LG AI Research partner to pioneer biomedical advancements
Two world-leading organizations are partnering to further expand AI capabilities in biomedical science and catalyze medical progress.